## UNITED STATES PATENT AND TRADEMARK OFFICE

\_\_\_\_\_

BEFORE THE PATENT TRIAL AND APPEAL BOARD

\_\_\_\_\_

## COALITION FOR AFFORDABLE DRUGS V LLC, Petitioner,

v.

## BIOGEN MA INC., Patent Owner.

Case: IPR2015-01136 U.S. Patent No. 8,399,514 B2

PATENT OWNER'S EXHIBIT LIST (as of August 11, 2015)



Exhibits	Description
Exhibit 2001	Hayman Capital Management, L.P. Form ADV Part 2A Brochure, June 1, 2015
Exhibit 2002	Investment Adviser Public Disclosure, Part 2 for Hayman Capital Management, L.P., http://www.adviserinfo.sec.gov/iapd/content/viewform/adv/Sec tions/iapd_Adv2Brochures.aspx?ORG_PK=146896&RGLTR_PK=50000&STATE_CD=&FLNG_PK=034480240008017C01 3E73700561A20D056C8CC0 (retrieved June 25, 2015).
Exhibit 2003	United States Securities and Exchange Commission Form D for Hayman Orange Fund SPC-Segregated Portfolio A, dated April 9, 2015.
Exhibit 2004	Restatement (Second) of Torts § 682 (1977)
Exhibit 2005	Cartwright v. Wexler, Wexler & Heller, Ltd., 369 N.E.2d 185 (Ill. App. Ct. 1977)
Exhibit 2006	Lader v. Benkowitz, 188 Misc. 906, 66 N.Y.S.2d 713 (Sup. Ct. 1946)
Exhibit 2007	157 Cong. Rec. S936-53 (daily ed. Feb. 28, 2011)
Exhibit 2008	File Wrapper for U.S. Provisional Application No. 60/888,921, filed February 8, 2007
Exhibit 2009	Final Office Action dated October 12, 2012, in U.S. Patent Application No. 13/372,426
Exhibit 2010	Application Data Sheet and Inventor Declaration filed February 13, 2012, for U.S. Patent Application No. 13/372,426
Exhibit 2011	Electronic Patent Application Fee Transmittal and Electronic Acknowledgement Receipt dated August 7, 2009, in U.S. Patent Application No. 12/526,296
Exhibit 2012	Reply to Final Office Action filed December 12, 2012, in U.S. Patent Application No. 13/372,426



Exhibits	Description
Exhibit 2013	Joseph A. DiMasi, Success rates for new drugs entering clinical testing in the United States, 58 CLIN. PHARMACOL. THER. 1 (1995)
Exhibit 2014	Joseph A. DiMasi, <i>Risks in new drug development: Approval success rates for investigational drugs</i> , 69 CLIN. PHARMACOL. THER. 297 (2001)
Exhibit 2015	Avanir Pharmaceuticals (AVNR), Crashes as Multiple Sclerosis Drug Fails Phase 2 Trial (December 11, 2013), http://www.biospace.com/News/avanir-pharmaceuticals-crashes-as-multiple/318325
Exhibit 2016	A. I. Graul et al., Overcoming Further Challenges in the Pharma/Biotech Industry: 2007 Update, 21 DRUG NEWS PERSPECT. 44 (2008)
Exhibit 2017	A. I. Graul & J.R. Prous, <i>Overcoming the Challenges in the Pharma/Biotech Industry</i> , 20 DRUG NEWS PERSPECT. 57 (2007)
Exhibit 2018	H.R. REP. No. 112-98, pt. 1 (2011)
Exhibit 2019	Ex parte McGaughey, 6 U.S.P.Q.2d 1334 (BPAI Mar. 4, 1988)
Exhibit 2020	Ex parte Raychem Corp., 25 U.S.P.Q.2d 1265 (BPAI June 30, 1992)
Exhibit 2021	Declaration of Richard A. Rudick, M.D. Under 37 C.F.R. §1.132 filed on August 3, 2012 in U.S. Patent Application No. 13/372,426
Exhibit 2022	Notice of Allowance and Fees Due dated December 26, 2012 in U.S. Patent Application No. 13/372,426

Respectfully submitted,

Dated: August 11, 2015

By: / Maureen D. Queler /

Michael I. Elibbert, Pag. No. 33, 234

Michael J. Flibbert, Reg. No. 33,234 Maureen D. Queler, Reg. No. 61,879 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP



901 New York Avenue, NW Washington, DC 20001-4413 (202) 408-4000

Counsel for Patent Owner



## **CERTIFICATE OF SERVICE**

The undersigned hereby certifies that copies of the foregoing **PATENT OWNER'S EXHIBIT LIST and Exhibits 2008-2022** were served on August 11,

2015, via electronic mail directed to counsel of record for the Petitioner at the following:

Robert W. Hahl Neifeld IP Law, PC, 4813-B Eisenhower Avenue, Alexandria, VA 22304 rhahl@neifeld.com

Robert Mihail Neifeld IP Law, PC, 4813-B Eisenhower Avenue, Alexandria, VA 22304 rmihail@neifeld.com

Petitioner has agreed to electronic service.

Dated: August 11, 2015 By: /Maureen D. Queler/

Maureen D. Queler

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP

